Overview
Semaglutide selectively activates the GLP-1 receptor: glucose-dependent insulin secretion, glucagon suppression, slowed gastric emptying, reduced caloric intake. Half-life ~7 days.
Related clinical pages
- STEP trial results
- SELECT trial results
- FLOW trial results
- Mechanism of action
- Dosing & pharmacology
- Contraindications
- Side effects
Key facts, checked November 20, 2026
The Wegovy label describes semaglutide as a GLP-1 analogue with 94% sequence homology to human GLP-1 that binds to and activates the GLP-1 receptor. GLP-1 regulates appetite and caloric intake, and the receptor is present in brain areas involved in appetite; in animal studies semaglutide reached and activated neurons in those regions. The label says the exact mechanism of its cardiovascular benefit has not been established. Semaglutide also delays gastric emptying, which is why oral medicines taken at the same time may be absorbed differently.